drugset / Trial / NCT00958100
Raltegravir Switch for Toxicity or Adverse Events
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to verify the persistent control of the virus replication at 48 weeks after the simplification to tenofovir + emtricitabine + raltegravir or to lamivudine+abacavir+raltegravir in patients with optimal virological suppression without any virological failure to previous combined antiretroviral therapies needing a therapeutic switch for toxicity related issues or adverse events.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-11
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | — | — |
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Tenofovir | Small molecule | — | — |
| Subject | emtricitabine | Other / unclassified | — | — |
| Background | Raltegravir | Other / unclassified | — | — |